Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS

Class Action Settlement Overview - The United States District Court for the District of Maryland has approved a proposed class action settlement benefiting purchasers of Emergent BioSolutions Inc common stock (NYSE: EBS) between March 10, 2020, and November 4, 2021 [1] - A hearing is scheduled for February 27, 2025, to determine the fairness and adequacy of the proposed $40 million settlement, the Plan of Allocation, and the approval of attorneys' fees and expenses [2] - The Settlement Class includes all persons or entities who purchased or acquired Emergent common stock during the Settlement Class Period, excluding certain individuals and entities such as Settling Defendants, their immediate families, and affiliates [3] Settlement Details and Claims - The proposed settlement resolves allegations that Settling Defendants made material misrepresentations and omissions concerning Emergent's business operations, reported results, and internal controls, leading to inflated stock prices during the Settlement Class Period [4] - Lead Plaintiffs allege that the revelation of Settling Defendants' fraud caused statistically significant stock declines, injuring investors [4] - Settlement Class Members must submit a Proof of Claim and Release Form by February 4, 2025, to be eligible for recovery from the Net Settlement Fund [5] Exclusion and Objection Procedures - Settlement Class Members who wish to exclude themselves from the Settlement Class must submit a request for exclusion by February 6, 2025 [6] - Members who do not exclude themselves can object to the Settlement, Plan of Allocation, or Lead Counsel's request for attorneys' fees and expenses by February 6, 2025 [7] - All members of the Settlement Class who do not request exclusion will be bound by any Judgment entered in the Action pursuant to the Settlement Stipulation [6]